Eton Pharmaceuticals, Inc.
corporate_fare Company Profile
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for ETON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ETON spans 10-Q, 8-K, 4, 144.
Recent high-impact activity:
- Eton Pharma Jumps 20% Premarket as Q3 Revenue Triples and Full-Year Guidance Raised to $175M+
- Eton 10-Q: Q3 Sales $57.9M, Nine-Month Operating Cash Flow $49.9M, Cash Builds to $55.6M
- Eton Q3 Sales $57.9M, Up 158%; 2026 Revenue Guidance Raised to >$175M
- Eton Posts $1.06 Q3 EPS, Extending Blowout Earnings Streak
- Eton's ET-700 Pilot: Better Tolerability, Weaker Copper Blocking Than GALZIN
Financial Snapshot
Short Interest & Short Volume
5.43 days to coverFINRA reported short interest of 1,986,167 shares in ETON as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 47.8% of ETON volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.